ROOSTERBIO, INC.

FREDERICK, MD · Founded 2012 · Biotech · Private

Manufacturing platform for scalable production of 3D mesenchymal stem cell aggregates using thermoreversible microcarriers

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: FREDERICK, MD
Founded: 2012
Latest Form D: $6.9M, Mar 2024
Total capital: $11.9M

Federal grants: $216K; 1 award · 2015; Rank in peer group#17 of 17
Private capital raised: $11.7M; 4 Form D · last Mar 2024; 31 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 1; 13 pending · first 2021; Rank in peer group#3 of 17

Capital timeline

Latest events

Mar 2024Private capital raisedForm D · SEC · 4th filing$6.9M
Feb 2017Private capital raisedForm D · SEC · 3rd filing$1.3M
Dec 2016Private capital raisedForm D · SEC · 2nd filing$3.4M
Sep 2015Federal grantHealth and Human S · Phase I · Development of efficient and scalable bioreactor-based production of human Mesenchymal Stem Cell (hMSC) 3D aggregates using microparticles with thermo-reversible surfaces$216K
Jan 2014Private capital raisedForm D · SEC · 1st filing$100K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 17 peers

Line = median

Biotech · System

Federal grantsBelow median
Granted patents#3 · top 18%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Daniella KranjacDirectorNamed in SEC Form D filings
Jon RowleyExecutive Officer, DirectorNamed in SEC Form D filings
Margot ConnorExecutive Officer, DirectorNamed in SEC Form D filings
Martin WestbergDirectorNamed in SEC Form D filings
Rob CarlsonDirectorNamed in SEC Form D filings
Robert CarlsonDirectorNamed in SEC Form D filings

Show all 10 people

Robert PretiDirectorNamed in SEC Form D filings
Susan RileyDirectorNamed in SEC Form D filings
Timothy KellyExecutive Officer, DirectorNamed in SEC Form D filings
Uplaksh KumarExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 14

Jul 13, 2021GrantedReady-to-print Cells And Integrated DevicesUSPTOUS 11,058,106
Jun 24, 2021PendingMethods And Compositions Related To Extracellular Material Derived From Hypertonic Cell SolutionsUSPTOApplication 17055276
Oct 18, 2018PendingContainers For Closed System Single-use Bioreactors And Culture VesselsUSPTOApplication 15737906

Show all 14 patent records

Ready-to-print Cells And Integrated DevicesJul 13, 2021 · US 11,058,106Granted
Methods And Compositions Related To Extracellular Material Derived From Hypertonic Cell SolutionsJun 24, 2021 · Application 17055276Pending
Containers For Closed System Single-use Bioreactors And Culture VesselsOct 18, 2018 · Application 15737906Pending
Biopreserved Stem Cells On MicrocarriersAug 2, 2018 · Application 15747199Pending
Biopreserved Stem Cells On MicrocarriersApplication PCTUS2016043839Pending
Containers For Closed System Single-use Bioreactors And Culture VesselsApplication PCTUS2016038342Pending
Biopreserved Stem Cells On MicrocarriersApplication 62196401Pending
Containers For Closed System Single-use Bioreactors And Culture VesselsApplication 62182183Pending
Ready-to-print Cells And Integrated DevicesApplication PCTUS2015030260Pending
Methods And Compositions Related To Reducing Viscosity In Cell CultureApplication PCTUS2024047762Pending
Methods And Compositions Related To Reducing Viscosity In Cell CultureApplication 19521012Pending
Methods And Compositions Related To Reducing Viscosity In Cell CultureApplication 63583942Pending
Methods And Compositions Related To Extracellular Material Derived From Hypertonic Cell SolutionsApplication PCTUS2019032155Pending
Methods And Compositions Related To Extracellular Material Derived From Hypertonic Cell SolutionsApplication 62671074Pending

GALIBRA NEUROSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
Arena PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
Quercus Molecular Design, LLCSimilar federal contract value in Biotech · null in contracts
DESIGNMEDIX, INC.Similar federal contract value in Biotech · null in contracts
AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC.Similar federal contract value in Biotech · null in contracts
cAMPfield TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.